- 22 November 2025
- book chapter
- Published by Springer Nature
- p. 361-381
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A Review of Emerging and Non-US FDA-Approved Topical Agents for the Treatment of Basal Cell CarcinomaFuture Oncology, 2021
- Topical treatments for skin cancerAdvanced Drug Delivery Reviews, 2020
- Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled TrialJournal of Investigative Dermatology, 2017
- Imiquimod in dermatology: an overviewInternational Journal of Dermatology, 2016
- Topical pharmacotherapy for skin cancerJournal of the American Academy of Dermatology, 2014
- Topical pharmacotherapy for skin cancerJournal of the American Academy of Dermatology, 2014
- What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trialBMC Dermatology, 2012
- Topical Antineoplastic Agents in the Treatment of Mucocutaneous Diseases2011
- Discovery of immunopotentiatory drugs: current and future strategiesClinical and Experimental Immunology, 2002
- Further Studies With Topical 5-FluorouracilArchives of Dermatology, 1965